Schonfeld Strategic Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-23,304
| Closed | -$603K | – | 2561 |
|
|
2025
Q4 | $603K | Buy |
+23,304
| New | +$554K | ﹤0.01% | 1321 |
|
|
2025
Q1 | – | Sell |
-271,654
| Closed | -$5.12M | – | 2438 |
|
|
2024
Q4 | $5.12M | Sell |
271,654
-236,082
| -46% | -$4.14M | 0.03% | 497 |
|
|
2024
Q3 | $7.64M | Buy |
+507,736
| New | +$8.68M | 0.05% | 383 |
|
|
2024
Q1 | – | Sell |
-100,053
| Closed | -$3.38M | – | 2306 |
|
|
2023
Q4 | $3.38M | Buy |
+100,053
| New | +$2.93M | 0.02% | 632 |
|
|
2023
Q3 | – | Sell |
-102,823
| Closed | -$4.12M | – | 2165 |
|
|
2023
Q2 | $4.12M | Buy |
+102,823
| New | +$4.25M | 0.04% | 541 |
|
|
2023
Q1 | – | Sell |
-29,472
| Closed | -$1.14M | – | 2506 |
|
|
2022
Q4 | $1.14M | Sell |
29,472
-5,213
| -15% | -$254K | 0.01% | 1071 |
|
|
2022
Q3 | $1.84M | Sell |
34,685
-3,082
| -8% | -$171K | 0.02% | 903 |
|
|
2022
Q2 | $2.2M | Buy |
+37,767
| New | +$2.47M | 0.02% | 719 |
|
|
2021
Q4 | – | Sell |
-118,970
| Closed | -$6.66M | – | 2432 |
|
|
2021
Q3 | $6.66M | Buy |
118,970
+51,381
| +76% | +$2.96M | 0.07% | 360 |
|
|
2021
Q2 | $4.1M | Buy |
67,589
+42,026
| +164% | +$2.66M | 0.04% | 511 |
|
|
2021
Q1 | $1.79M | Buy |
+25,563
| New | +$1.83M | 0.02% | 700 |
|
|
2020
Q4 | – | Sell |
-13,100
| Closed | -$788K | – | 1799 |
|
|
2020
Q3 | $788K | Buy |
+13,100
| New | +$761K | 0.02% | 771 |
|
|
2020
Q2 | – | Sell |
-10,967
| Closed | -$368K | – | 1481 |
|
|
2020
Q1 | $368K | Buy |
+10,967
| New | +$456K | 0.02% | 676 |
|
|
2019
Q4 | – | Sell |
-82,200
| Closed | -$3.13M | – | 1442 |
|
|
2019
Q3 | $3.13M | Buy |
82,200
+12,600
| +18% | +$503K | 0.09% | 228 |
|
|
2019
Q2 | $3.03M | Buy |
69,600
+10,200
| +17% | +$433K | 0.11% | 225 |
|
|
2019
Q1 | $2.26M | Sell |
59,400
-39,611
| -40% | -$1.55M | 0.08% | 305 |
|
|
2018
Q4 | $4.26M | Buy |
+99,011
| New | +$4.62M | 0.16% | 172 |
|
|
2018
Q2 | – | Sell |
-55,731
| Closed | -$1.74M | – | 915 |
|
|
2018
Q1 | $1.74M | Buy |
+55,731
| New | +$1.98M | 0.13% | 226 |
|
|
2017
Q3 | – | Sell |
-5,962
| Closed | -$284K | – | 739 |
|
|
2017
Q2 | $284K | Sell |
5,962
-6,864
| -54% | -$318K | 0.03% | 493 |
|
|
2017
Q1 | $585K | Buy |
+12,826
| New | +$554K | 0.06% | 343 |
|
|
2016
Q3 | – | Sell |
-40,447
| Closed | -$1.36M | – | 507 |
|
|
2016
Q2 | $1.36M | Buy |
+40,447
| New | +$1.99M | 0.31% | 86 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Schonfeld Strategic Advisors's PCRX Position: Q1 2026 in Review
Schonfeld Strategic Advisors sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 23,304 shares — an estimated $603K sold.
Schonfeld Strategic Advisors first reported a position in PCRX in Q2 2016 and held it in 21 quarters. The position peaked at $7.64M in Q3 2024. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Schonfeld Strategic Advisors reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 23,304 Pacira BioSciences shares in Q1 2026, an estimated $603K.
- Schonfeld Strategic Advisors first reported a position in Pacira BioSciences in Q2 2016 and held it in 21 quarters.
- Schonfeld Strategic Advisors's Pacira BioSciences position peaked at $7.64M in Q3 2024.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.